A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, parallel group, placebo-controlled study evaluate the
preliminary efficacy and safety of MB-6 (320 mg/capsule, 6 capsules tid) versus placebo in
addition to standard chemotherapy in the treatment of patients with metastatic colorectal
cancer.